Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 11, 2012, Pages 1409-1417

  Niesters, Marieke ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic pain management; Ketamine; NMDA receptor antagonists; Norketamine; NR2B selective NMDAR antagonists; Pain

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANALGESIA; AREA UNDER THE CURVE; CHRONIC PAIN; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FIRST PASS EFFECT; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NUMBERS NEEDED TO TREAT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; KETAMINE; NEURALGIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84867570047     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.712686     Document Type: Review

References (58)

1. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-Daspartate (NMDA) receptors in pain: A review. Anesth Analg 2003;97:1108-16
2. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003;CD003351
3. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006;CD004603
4. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85:S3-14
5. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305
6. Chizh BA. Low dose ketamine: A therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007;21:259-71
7. Sigtermans M, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009;145:304-11
8. Swartjes M, Morariu A, Niesters M, et al. Nonselective and NR2B selective N-methyl-D-aspartic acid receptor antagonist produce antinociception and long-term relief of allodynia in acute neuropathic pain. Anesthesiology 2011;115:165-74
9. Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain 2009;147:107-15
10. Collins S, Sigtermans M, Dahan A, et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010;11:1726-42
11. Noppers I, Niesters M, Aarts L, et al. Ketamine for treatment of chronic non-cancer pain. Exp Opinion Pharmacother 2010;11:2417-29
12. Sang CN, Weaver JJ, Jinga L, et al. The NR2B subunit-selective NMDA receptor antagonist CP-101,606 reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Soc Neurosci Abst 2003;814-19
13. Max MB, Byassmith MG, Gracely RH, et al. Intravenous-infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia -A double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995;18:360-8
14. Bell RF. Ketamine for chronic non-cancer pain. Pain 2009;141:210-14
15. Niesters M, Martini C, Dahan A. Ketamine for chronic pain-Risks and benefits. Br J Clin Pharmacol 2012; submitted
16. 16. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: A prospective, randomized, double blind trial. Pain Physician 2010;13:245-9
17. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-Multiple drug targets and multiple uses. Curr Pharmacol Des 2005;11:2977-94
18. Childers WE Jr, Baudy RB. N-methyl-D-aspartate antagonists and neuropathic pain: The search for relief. J Med Chem 2007;50:2257-62
19. Wu LJ, Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurother 2009;6:693-702
20. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacother 2006;6:68-74
21. Alkire MT, Hudgetz AG, Tononi G. Consciousness and anesthesia. Science 2008;322:876-80
22. Qu XX, Cai J, Li MJ, et al. Role of spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol 2009;215:298-307
23. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunits in dorsal horn. Neuropharmacol 1999;8:611-23
24. Borsook D. Ketamine and chronic pain-Going the distance. Pain 2009;145:271-2
25. Hirota K, Lambert DG. Ketamine: new used for an old drug? Br J Anaesth 2011;107:123-6
26. Domino EF. Taming the ketamine tiger. Anesthesiology 2010;113:678-86
27. Geisslinger G, Hering W, Thomann P, et al. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993;70:666-71
28. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003;24:37-43
29. Miller RD, Afton-Bird G, Fleisher LA. Miller's anesthesia. 6th edition. Elsevier Churchill Livingstone; Philadelphia: 2004
30. Sigtermans M, Dahan A, Mooren M, et al. S(+)-ketamine effect on experimental pain and cardiac output: A population pharmacokinetic- pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009;111:892-903
31. Adams HA, Bauer R, Gebhart B, et al. Total iv anesthesia with S(+)-ketamine in orthopaedic geriatric surgery: Endocrine stress reaction, hemodynamics and recovery. Anaesthetist 1994;42:92-100
32. Morgan CJA, Perry EB, Cho H-S, et al. Greater vulnerability to the amnesic effects of ketamine in males. Pyschopharmacol 2006;187:405-14
33. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in Ndemethylation of ketamine in human liver microsomes. Drug Metab Dis 2001;29:887-90
34. Hijazi Y, Boulieu R. Contribution of CYP3A4, CP2B6 and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;30:853-8
35. Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administrations. Anesthesiologist 2011;114:1435-45
36. Hagelberg NM, Peltoniemi MA, Saari et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2009;14:625-9
37. Koppel C, Arndt I, Ibe K. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur J Drug Metab Pharmacokinet 1990;15:259-63
38. Sigtermans M, Dahan A, Mooren R, et al. S(+)-ketamine effect on experimental pain and cardiac output: A population pharmacokineticpharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009;111:892-903
39. Sigtermans M, Noppers I, Sarton E, et al. An observational study on the effect of S(+)-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2010;14:302-7
40. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997;333:99-104
41. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, et al. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008;90:675-85
42. Olofsen E, Noppers I, Niesters M, et al. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 2012; In press
43. Mitchell AC. Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliat Med 1999;13:427-8
44. Niesters M, Dahan A, Swartjes M, et al. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011;152:656-63
45. Schüttler J, Stanski DR, White PF, et al. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987;15:241-53
46. Herd DW, Anderson BJ, Keene NA, Holford NHG. Investigating the pharmacodynamics of ketamine in children. Ped Anesth 2008;18:36-42
47. Christoph T, Schiene K, Englberger W, et al. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacol 2006;51:12-17
48. Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic- pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011;15:258-67
49. Noppers I, Niesters M, Aarts L, et al. E. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases. Pain 2011;142:2173-8
50. Nicholson KL, Mansbach RS, Menniti FS, Balster RL. The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101,606 in rats and rhesus monkeys. Behav Pharmacol 2007;18:731-43
51. Canet J, Castillo J. Ketamine: A familiar drug we trust. Anesthesiology 2012;116:6-8
52. Eisenberg E, Midbari A, Haddad M, Pud D. Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects. Pain 2010;151:104-9
53. Yarnitsky D, Granot M, Nahman-Averbuch H, et al. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153:1193-8
54. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-Daspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64
55. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies rapid antidepressant effects of NMDA antagonists. Science 2010;20:329:959-64
56. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Iontophoretic administration of S (+)-ketamine in patients with intractable central pain: A placebo-controlled trial. Pain 2005;118:224-31
57. Nickolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: A central neuropathic disorder maintained by peripheral input. Pain 1996;67:69-77
58. Eichenberger U, Neff F, Sveticic G, et al. Chronic phantom limb pain: The effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg 2008;106:1265-73